Triple-Drug cocktail aims to tackle Hard-to-Treat cancers
NCT ID NCT07681297
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests a combination of three drugs—tislelizumab, bevacizumab, and capecitabine—in people with advanced solid tumors. The trial focuses on two challenging groups: those whose cancers have stopped responding to immunotherapy and those with tumors that have spread to the brain or central nervous system. The goal is to find a safe dose and see if the combination can shrink tumors or slow their growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab, bevacizumab, and capecitabine
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have stopped responding to immunotherapy or have spread to the brain.
What could go wrong
This is an early-phase study (Phase 1/2) with a small number of participants, so the benefits are not yet proven. The drug combination may cause significant side effects, and it may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- NIR Device for Breast Flap Perfusion Study (NCT07680296)
- Long-Term Heart Effects of Anthracycline in Brea NCT07680855
- Trastuzumab + RAD001 for HER2+ Breast Cancer NCT00317720
- AMPLIFI: Web-Based Lifestyle Program for Cancer NCT04000880
- Cognitive Stimulation for Elderly Breast Cancer NCT04261153
- Cognitive difficulties after breast cancer: feas NCT04213365
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National University Cancer Institute, Singapore, National University Health System
Singapore, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••